Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.66 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.66 |
| ▸ | HTR1D | P28221 | 1/20 | 0.66 |
| ▸ | HTR1B | P28222 | 1/20 | 0.66 |
| ▸ | HTR2C | P28335 | 1/20 | 0.66 |
| ▸ | HTR1E | P28566 | 1/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.66 |
| ▸ | HTR7 | P34969 | 1/20 | 0.66 |
| ▸ | HTR2B | P41595 | 1/20 | 0.66 |
| ▸ | HTR6 | P50406 | 1/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.63 |
| ▸ | APAF1 | O14727 | 1/20 | 0.63 |
| ▸ | RECQL | P46063 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1911320 | 1.00 | HTR2A (0.66) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL28878178 | 0.87 | HTR2A (0.67) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL14473032 | 0.85 | HTR2A (0.69) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL22803428 | 0.85 | HTR2A (0.69) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL7149267 | 0.85 | SMN1; SMN2 (0.62) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL8246556 | 0.85 | HTR2A (0.69) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL360064 | 0.85 | HTR2A (0.69) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL24178325 | 0.84 | ADRB3 (0.63) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL24820010 | 0.84 | ADRB1 (0.62) | HTR2AADRB1HTR1AADRA2ASLC6A2 | |
| SCHEMBL24820009 | 0.84 | ADRB1 (0.62) | HTR2AADRB1HTR1AADRA2ASLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| EP-3038618-B1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | UNIV VANDERBILT (US) | 2020-10-14 | — | — | EP | disclosed |
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | VANDERBILT UNIVERSITY | 2018-09-13 | — | — | US | disclosed |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | VANDERBILT UNIVERSITY (US) | 2018-06-26 | — | — | US | disclosed |
| US-9802959-B2 | Method of producing (4R,12aS)-7,9-dihalo-4-methyl-3,4,12,12a-tetrahydro-2H-pyrido[1′,2′:4,5]pyrazino[2,1-b][1,3]oxazine-6,8-diones | SHIONOGI & CO., LTD. (JP) | 2017-10-31 | — | — | US | disclosed |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2017-08-24 | — | — | US | disclosed |
| US-9650394-B2 | Methods of producing substituted (3S,11aR)-6-hydroxy-3-methyl-5,7-dioxo-2,3,5,7,11,11a-Hexahydrooxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamides | SHIONOGI & CO., LTD. (JP) | 2017-05-16 | — | — | US | disclosed |
| US-9505783-B2 | Method of producing pyrone and pyridone derivatives | SHIONOGI & CO., LTD. (JP) | 2016-11-29 | — | — | US | disclosed |
| US-9428448-B2 | Compounds and methods of treating obesity | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2016-08-30 | — | — | US | disclosed |
| US-20160229870-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2016-08-11 | — | — | US | disclosed |
| EP-2013211-B1 | PURINE DERIVATIVES FOR USE AS ADENOSIN A2A RECEPTOR AGONISTS | NOVARTIS AG (CH) | 2012-03-14 | — | — | EP | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-8114878-B2 | 6,7-dihydrothieno[3,2-d]pyrimidine for the treatment of inflammatory diseases | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-02-14 | — | — | US | disclosed |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-09-02 | — | — | US | disclosed |
| EP-1956016-A1 | Bicyclic acyltryptophanols | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-08-13 | — | — | EP | disclosed |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118793-A1 | DIHYDROTHIENOPYRIMIDINE FOR TREATING INFLAMMATORY DISORDERS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |
| EP-1847543-A1 | Dihydrothienopyrimidines for the treatment of inflammatory diseases | Boehringer Ingelheim Pharma GmbH & Co. KG (DE) | 2007-10-24 | — | — | EP | disclosed |
| WO-2007017289-A2 | ACYLTRYPTOPHANOLS FOR FERTILITY CONTROL | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-02-15 | — | — | WO | disclosed |
| US-5455262-A | Treating arthritis, tumor metastasis, periodontal disease, corneal ulceration, bone resorption diseases, glomerular diseases | FLORIDA STATE UNIVERSITY (US) | 1995-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180258039-A1 | SUBSTITUTED INDOLE MCL-1 INHIBITORS | MCL1, BCL2, BCL2L1 | HTR2A 586/4885ADRB1 2849/4885HTR1A 813/4885 |
| US-20080096882-A1 | PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system | PDE4A, PDE4B, PDE12 | HTR2A 3590/4885ADRB1 689/4885HTR1A 2247/4885 |
| US-20100222585-A1 | PREPARATION OF DIHYDROTHIENO [3, 2-D] PYRIMIDINES AND INTERMEDIATES USED THEREIN | DPYD, TYMS, DHFR | HTR2A 3255/4885ADRB1 2961/4885HTR1A 2158/4885 |
| US-10005728-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR2A 586/4885ADRB1 2849/4885HTR1A 813/4885 |
| US-20170240564-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, DRD4, PYM1 | HTR2A 2840/4885ADRB1 1744/4885HTR1A 1995/4885 |
| US-20160229870-A1 | METHODS OF PRODUCING COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | XDH, VRK2, PYM1 | HTR2A 3450/4885ADRB1 1282/4885HTR1A 2176/4885 |
| US-10954193-B2 | Substituted indole Mcl-1 inhibitors | MCL1, BCL2, BCL2L1 | HTR2A 586/4885ADRB1 2849/4885HTR1A 813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.